Shijiazhuang Yiling Pharmaceutical Future Growth

Future criteria checks 4/6

Shijiazhuang Yiling Pharmaceutical is forecast to grow earnings and revenue by 43.4% and 18.1% per annum respectively. EPS is expected to grow by 43.5% per annum. Return on equity is forecast to be 12.1% in 3 years.

Key information

43.4%

Earnings growth rate

43.5%

EPS growth rate

Pharmaceuticals earnings growth	18.6%
Revenue growth rate	18.1%
Future return on equity	12.1%
Analyst coverage	Low
Last updated	14 Oct 2024

Recent future growth updates

Recent updates

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?

Sep 25

Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity

Aug 07

Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30

Jul 15

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?

May 26

Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)

May 05

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially

May 02

Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?

Mar 01

Earnings and Revenue Growth Forecasts

SZSE:002603 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	13,562	1,912	N/A	2,540	5
12/31/2025	11,960	1,621	N/A	2,253	5
12/31/2024	10,588	1,366	N/A	2,000	5
6/30/2024	8,132	277	-554	-261	N/A
3/31/2024	8,906	454	-395	-128	N/A
12/31/2023	10,318	1,352	-155	155	N/A
9/30/2023	13,162	2,707	2,162	2,408	N/A
6/30/2023	13,757	2,920	2,525	2,735	N/A
3/31/2023	13,746	3,081	3,087	3,343	N/A
1/1/2023	12,533	2,363	3,274	3,488	N/A
9/30/2022	9,951	1,535	1,094	1,473	N/A
6/30/2022	9,787	1,428	1,884	2,253	N/A
3/31/2022	9,170	1,153	575	1,141	N/A
1/1/2022	10,117	1,344	-145	529	N/A
9/30/2021	10,447	1,426	-576	300	N/A
6/30/2021	10,192	1,469	-1,702	-518	N/A
3/31/2021	10,117	1,455	-1,005	179	N/A
12/31/2020	8,782	1,219	441	1,586	N/A
9/30/2020	7,925	1,048	442	1,314	N/A
6/30/2020	7,328	866	779	1,467	N/A
3/31/2020	6,609	756	529	1,043	N/A
12/31/2019	5,825	607	-386	69	N/A
9/30/2019	5,336	612	-193	208	N/A
6/30/2019	5,098	606	19	300	N/A
3/31/2019	4,784	577	370	593	N/A
1/1/2019	4,815	599	-115	72	N/A
9/30/2018	4,848	653	320	462	N/A
6/30/2018	4,537	649	287	428	N/A
3/31/2018	4,347	632	N/A	66	N/A
12/31/2017	4,081	541	N/A	115	N/A
9/30/2017	3,972	555	N/A	242	N/A
6/30/2017	4,036	569	N/A	206	N/A
3/31/2017	4,050	570	N/A	508	N/A
12/31/2016	3,850	533	N/A	641	N/A
9/30/2016	3,665	527	N/A	507	N/A
6/30/2016	3,538	510	N/A	426	N/A
3/31/2016	3,439	489	N/A	181	N/A
12/31/2015	3,185	430	N/A	132	N/A
9/30/2015	3,161	395	N/A	60	N/A
6/30/2015	3,089	376	N/A	-35	N/A
3/31/2015	2,980	377	N/A	56	N/A
12/31/2014	2,921	354	N/A	106	N/A
9/30/2014	2,877	312	N/A	-80	N/A
6/30/2014	2,871	294	N/A	98	N/A
3/31/2014	2,711	275	N/A	-35	N/A
12/31/2013	2,490	244	N/A	55	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002603's forecast earnings growth (43.4% per year) is above the savings rate (2.9%).

Earnings vs Market: 002603's earnings (43.4% per year) are forecast to grow faster than the CN market (23.7% per year).

High Growth Earnings: 002603's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002603's revenue (18.1% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 002603's revenue (18.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002603's Return on Equity is forecast to be low in 3 years time (12.1%).

Shijiazhuang Yiling Pharmaceutical Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target decreased by 20% to CN¥28.26

Price target increased by 7.9% to CN¥37.69

Price target increased to CN¥33.05

Price target increased to CN¥31.49

Price target increased to CN¥28.01

Price target decreased to CN¥21.04

Recent updates

Shijiazhuang Yiling Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.24 in 2Q 2023)

Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity

Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30

Dividend reduced to CN¥0.30

Shijiazhuang Yiling Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend Per 10 Shares for 2023

Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially

Shijiazhuang Yiling Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Shijiazhuang Yiling Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.72 in 1Q 2023)

Shijiazhuang Yiling Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?

Shijiazhuang Yiling Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.22 in 3Q 2022)

Price target decreased by 20% to CN¥28.26

Second quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.34 in 2Q 2022)

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023

Now 21% undervalued after recent price drop

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022

Price target increased by 7.9% to CN¥37.69

First quarter 2023 earnings released: EPS: CN¥0.72 (vs CN¥0.29 in 1Q 2022)

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target increased to CN¥33.05

Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.15 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.17 in 2Q 2021)

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Final Dividend on Share A for 2021, Payable on July 19, 2022

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥31.49

Now 21% undervalued

Investor sentiment improved over the past week

Now 23% undervalued

Investor sentiment improved over the past week

Price target increased to CN¥28.01

Investor sentiment improved over the past week

Price target decreased to CN¥21.04

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.18 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.57 (vs CN¥0.37 in 1Q 2020)

Consensus revenue estimates increase to CN¥12.3b

Full year 2020 earnings released: EPS CN¥1.02 (vs CN¥0.51 in FY 2019)

Investor sentiment improved over the past week

Yiling Pharmaceutical Receives Approval for Lianhua Qingwen Capsules from The Pharmacy and Poisons Board of the Ministry of Health of Kenya

New 90-day low: CN¥21.90

Shijiazhuang Yiling Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 09, 2021

New 90-day low: CN¥22.96

Investor sentiment improved over the past week

New 90-day high: CN¥29.15

New 90-day low: CN¥24.64

New 90-day low: CN¥25.46

Yiling Pharmaceutical Receives Certificate of Registration for Dietary Supplements

Third quarter earnings released

Shijiazhuang Yiling Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Preparation Products of Yiling Pharmaceutical Co., Ltd. Approves by FDA for Launch in the US Market

New 90-day low - CN¥27.35

Analysts increase revenue estimates to CN¥9.50b